Industry Outlook 2025: Business Viability and Global Collaboration
Pharmaceutical Technology® spoke with Alexander Seyf, CEO and co-founder of Autolomous, about which trends from 2024 he expects to impact the bio/pharmaceutical industry in 2025.
Being realistic about the viability of business, finances, technology, and the success of drug products, as well as getting back to the basics, are trends from 2024 that have impacted the bio/pharmaceutical industry, according to Alexander Seyf, CEO and Co-Founder of Autolomous. “We're seeing people going back to the drawing board and thinking at the same time [not just the] science, but also the viability of having it as a business,” says Seyf. “I think that's a very positive [trend], because sometimes we need little bit of nudge in the in the shoulder to really guide us forward.”
Seyf also stresses that the industry needs to break out of a “siloed” mentality and embrace working together. Part of making business viable is harmonization and thinking globally. “And one of the key elements, I would say, is we need support from governments. We need support from policy makers,” Seyf says. “And right now, I've seen a good trend in the United States this year that they begin to realize that this is an industry to invest in, and we need to think a little bit differently than we do for pharma. However, I also see the whole kind of healthcare situation in US can be little bit difficult to move it to a more rational change, or to more radical change. However, in Europe, we have the benefit of national health services, and … politicians start realizing the new modality of medicine. There have been a number of talks, and, also, I believe it was mentioned in the parliament. So, we see good trends, both from a Europe perspective, but also a UK [United Kingdom] perspective.”
Click the video above to watch the full interview.
About the speaker
Alexander Seyf, CEO and Co-Founder of Autolomous
Alexander Seyf is CEO and Co-Founder of Autolomous.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
